Yajin Chen

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Anticancer Drugs Cause Release of Exosomes with Heat Shock Proteins from Human Hepatocellular Carcinoma Cells That Elicit Effective Natural Killer Cell Antitumor Responses in Vitro

Lihong Lv, Yun-Le Wan, Yan Lin et al. · Journal of Biological Chemistry · 2012 · 470 citations · Full text

Life Sciences, Immunology, Oncology +13

TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma

Wenliang Tan, Xuan Luo, Wenda Li et al. · EBioMedicine · 2018 · 109 citations · Full text

Medicine, Oncology, Pharmacology +16

Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial

Zhenggang Ren, Michel Ducreux, Ghassan K. Abou‐Alfa et al. · Liver Cancer · 2022 · 78 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma

Wenliang Tan, Kelin Zhang, Xinming Chen et al. · Journal of Advanced Research · 2022 · 54 citations · Full text

Medicine, Oncology, Pharmacology +17